Lidocaine — research review 1

...and while lidocaine, a sodium channel blocker, can be incredibly effective for localized neuropathic pain, especially as a patch or IV, the long-term picture regarding aging and all-cause mortality is complex.

Right. We know chronic pain itself is a problem for biological aging. For example, a study in GeroScience 2025 (PMID 39847262) found that painful diabetic neuropathy is linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy. So, treating pain is important.

Absolutely. But with interventions like lidocaine, the question becomes: does long-term use, even with good pain relief, introduce its own risks that impact longevity or quality of life in other ways? We’re talking about potential side effects like falls from sedation, or cognitive issues, which are especially concerning in older adults.

And what about all-cause mortality? The direct evidence specifically linking long-term lidocaine use to all-cause mortality or biological aging markers in humans, beyond general risks associated with medication use in the elderly, isn't firmly established. We don't have large-scale, long-term trials definitively showing it either accelerates or decelerates aging processes or directly impacts mortality.

Exactly. While the benefits for acute or localized chronic pain are clear for many, particularly under supervised care, the evidence on its direct impact on epigenetic clocks or overall lifespan is still being investigated. It highlights the crucial balance between managing pain's negative effects on aging and understanding the full long-term profile of treatments. We need more research to fully understand these broader impacts.